[Pharmacokinetics of cefotiam in patients undergoing continuous ambulatory peritoneal dialysis]. 1988

N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
Third Department of Internal Medicine, School of Medicine, Kinki University.

The pharmacokinetics of cefotiam (CTM) was investigated in 7 patients undergoing continuous ambulatory peritoneal dialysis (CAPD). One gram of CTM was infused either intravenously (i.v. group) or intraperitoneally (i.p. group). In the i.v. group, the serum concentration of CTM at 6 hours after infusion was 25.9 mg/L and the half-life value was 5.09 hours, while the peak value of CTM in dialysate was 12.4 mg/L. In the i.p. group without peritonitis, the dialysate concentration of CTM at 6 hours after infusion was 108.6 mg/L. The serum concentration at 15 minutes after infusion was 3.0 mg/L, the corresponding peak value was 14.0 mg/L at 4 and 6 hours after infusion.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
July 1992, Antimicrobial agents and chemotherapy,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
January 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
April 1981, Antimicrobial agents and chemotherapy,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
May 1984, Antimicrobial agents and chemotherapy,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
March 1984, Antimicrobial agents and chemotherapy,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
August 1983, Antimicrobial agents and chemotherapy,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
June 1990, Clinical pharmacokinetics,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
January 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
May 1988, Journal of clinical pharmacology,
N Itagaki, and H Hasegawa, and M Tsujino, and K Takahashi, and Y Yamamoto, and A Imada, and A Horiuchi
October 1988, Clinical nephrology,
Copied contents to your clipboard!